In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 211 to 220 of 399

TitleTypeExpected publication date
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Technology appraisal guidanceTBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mental health guidelinesNICE guidelineTBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237Technology appraisal guidanceTBC
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NICE guidelineTBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All